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1. Introduction 
A number of neutral oligosaccharides have been 
isolated from human urine. The excretion of some of 
these oligosaccharides depends on the donor’s blood 
group [l-3], dietary status [ 2,4], or some physiolog- 
ical [5-71 and pathological [ 1,2,8-151 conditions. 
Patients with lysosomal storage diseases in which the 
degradation of glycoproteins is affected excrete abnor- 
mally large quantities of oligosaccharides which are 
presumably the substrates of the defective enzymes. 
Mucolipidosis II (Icell disease, ML II) and muco- 
lipidosis III (ML III) probably result from defective 
post-translational processing of lysosomal enzymes in 
certain cells [ 16,171, which cause a multiple lysosomal 
hydrolase deficiency and increased excretion of sialic 
acidcontaining oligosaccharides [111. Apart from the 
sialylated oligosaccharides there has been no report of 
increased amounts of neutral oligosaccharides in urine 
from these patients. However, routine gas chromatog- 
raphy-mass spectrometry (GLC-MS) screening of 
human urinary oligosaccharides howed that a hitherto 
undescribed neutral disaccharide is also excreted by 
patients with ML II and ML III and to a lesser extent 
by normal individuals and patients with other lysoso- 
mal storage disorders. We now describe the isolation 
and structure of this disaccharide. 
2. Materials and methods 
Urine was collected without dietary restriction 
from normal individuals and patients with various 
metabolic disorders. The samples were immediately 
frozen and stored at -2O’C until used. Ultrafiltration 
of filtered urine was performed at 4°C using an 
Amicon Hollow Fibre HP 05 system. Samples were 
concentrated by rotary evaporation at <25’C. Gel 
chromatography was done in a column (10 X 110 cm, 
V, 3260 ml) of Sephadex G-l 5 fine (Pharmacia, 
Uppsala) eluted with distilled water containing sodium 
azide (0.02%) at a flow rate of 4 ml/mm. Column 
fractions and whole urine samples were deionised by 
passage through columns packed with AG 5OW-X8 
(100-200 mesh), H’ form, and AG 3-X4A (100-200 
mesh), OH- form (Biorad Labs, Richmond CA). 
Whatman no. 3 papers were used for descending chro- 
matography using the following systems: 
(a) Ethyl acetate/pyridine/water, (2/l/2, by vol., 
upper phase); 
(b) Ethyl acetate/acetic acid/water, (3/1/l, by vol.); 
(c) Propan-I-al/ethyl acetate/water, (6/l/3, by vol.); 
(d) Ethyl acetatelpyridine acetic acid/water, (5/5/l/3, 
by vol.); 
(e) Ethyl acetate/pyridine/water, (12/5/4, by vol.). 
Papers were stained with a silver dip reagent [ 181. A 
calorimetric method was used for determining total 
hexose in fractions eluted from gel chromatography 
columns [ 191. Optical rotations were determined 
using a Perkin-Elmer 2411 polarimeter. Sugar analysis 
was performed by gas-liquid chromatography (GLC) 
and mass spectrometry (MS) [20,21]. Methylation 
analysis was done as in [22]. Analysis of permethyl- 
ated disaccharide was done using a glass capillary col- 
umn (25 m X 0.25 mm) wall coated with SE-30. The 
separation was performed between 23O’C (isothermal, 
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20 min) and 330°C (2’C/min). Isomaltotetraose (IM4 
200 pg) was added as an internal standard. The iden- 
tification and quantitation of the urinary disaccharides 
were carried out by GLC-MS as in [ 231. Urinary 
creatinine was also determined [24]. 
3. Results and discussion 
Routine GLC-MS screening of urinary oligosac- 
charides frequently indicates the presence of small 
amounts of a disaccharide with the structure, hexose- 
N-acetylhexosamine (hex-hexNAc). A patient (B. B.) 
known to suffer from ML II excreted higher than 
normal amounts of this compound, and since suffi- 
cient quantities of this urine were available, the 
disaccharide was isolated and characterised. The ultra- 
filtered urine (3 1) was concentrated to 400 ml by 
rotatory evaporation and-applied to the Sephadex 
G-l 5 column (maximum load = 80 ml/column). Frac- 
tions were tested for hexose content and the disac- 
charide region was pooled, deionised by ion-exchange 
chromatography and concentrated. After fractionation 
by preparative paper chromatography in system (b), 
one of the fractions (Rlactose = 1.5) was purified 
further by preparative paper chromatography in sys- 
tem (a), yielding 3 mg disaccharide. The purity of the 
compound was examined by paper chromatography 
using systems (c)-(e). A single component was 
observed in all 3 systems, and was shown by GLC- 
100 
50 
MS of the reduced and permethylated derivative to 
contain 4-O-hexopyranosyl-2-acetamido-2-deoxy- 
hexose. The mass spectrum of this compound is 
shown in fig.1. The A-series of fragments at m/e 219, 
187 and 155 indicate the permethylated hexopyranose 
residue. The ald-Jr and ald’ fragments at m/e 337 and 
277 indicate a permethylated acetamido-deoxyhexi- 
tol-‘H residue. The fragment at m/e 13 1, obtained by 
cleavage of the alditol chain, indicates a 2acetamido 
residue. The presence of an alditol cleavage fragment 
at m/e 175 and the absence of a fragment at m/e 133 
suggests that the linkage between the sugar units is 
[l-4]. 
Sugar analysis indicated mannose and 2-acetamido- 
2-deoxyghrcose in equimolar proportions. The optical 
rotation (aD *’ = -0.04, c = 1.55, water) demonstrated 
that the linkage between the sugar residues is /3-, 
assuming the Dconfiguration for both sugar units. 
Methylation analysis of the reduced disaccharide gave 
2,3,4,6-te tra_O-methyl-D-mannose and 1,3,5,6-tetra- 
O-methyl-2-(N-methyl)acetamido-2-deoxy-D-glucitol 
(and some 1,3,5,6-tetra-O-methyl-2-acetamido-2- 
deoxy-D-glucitol). The latter two derivatives have 
been identified in [25]. From the above data the 
structure of the disaccharide is 4-WD-Maw- 
GlcNAcp. This compound was obtained from the 
trisaccharide, cu-D-Ma.np-(l -3)Q-D-Manp(l -4)-D- 
GlcNAc by enzymic digestion using a-mannosidase 
[251. 
GLC of reduced and permethylated urine gives a 
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Fig.1. Mass spectrum of reduced (Na B’H,) and permethylated Man+(1-4)GlcNAc. 
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Fig.2. Gas chromatogram of reduced (NaB*H,) and permethylated urine from a patient with ML II. 
complex picture (fig.2), but the hex-hexNAc region 
of the trace is usually well separated from other com- 
ponents. However, just one discrete peak in this region 
is rarely encountered when the GLC is run under 
optimal conditions. In fig.2, peaks (a,b) have identical 
retention times to Gal+?<1 -4)-GlcNAc and Man+ 
(l-4)-GlcNAc, respectively, and on GLC-MS analysis 
have mass spectra in accordance with these structures 
(fig.1). However, peak (c) does not give characteristic 
carbohydrate fragments. In other urine samples 
another non-carbohydrate component occurs in vari- 
able amounts and has the same retention time as Man- 
/3(1--I)-GlcNAc. Consequently, quantitation of this 
disaccharide in urine cannot be performed by GLC 
alone. We have corrected for the impurity by mea- 
suring the relative intensities of the total ion current, 
and the characteristic ald’ion of Man&(1 -4)GlcNAc, 
m/e 277, in the samples and the pure compound. 
The amount of ManQ(l-4)-GlcNAc excreted by 
patients with a number of lysosomal storage diseases 
is shown in table 1. As can be seen, the patients with 
ML II and ML III excrete slightly more of this disac- 
charide than patients with other diseases, although 
this may not be significant. Urine from normal indi- 
viduals usually contains <l mg/mmol creatinine. The 
only disease in which a significant increase in the 
excretion of this disaccharide should occur is P-manno- 
sidosis, as yet unknown in man, but described in 
goats [26]. 
Table 1 
The urinary excretion of Man-p-(1 -4)-GlcNAc by patients 
with lysosomal storage diseases 
Patient Disease ManGlcNAc excreted 
(mg/mmol creatinine) 
P. P. 
B. B. 
A. S. 
T. Y. 
M. 0. 
A. 0. 
J. G. 
K. A. 
c. w. 
H. K. 
F. Z. 
s. z. 
G. S. 
A. J. 
J. S. 
ML1 2.1 
ML II 4.3 
ML II 2.4 
ML III 5.1 
ML IV 1.5 
ML IV 1.0 
ML IV 0.8 
Tay Sachs 0.1 
Sandhoff 0.3 
orMannosidosis 0.3 
Fucosidosis 0.2 
Fucosidosis 1.0 
Fucosidosis 0.3 
Aspartylglucosaminuria trace 
Aspartylglucosamiuuria trace 
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